Bausch Health Companies Inc. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Q3 2026 consolidated revenues of $2.94B (+10% reported, +8% organic YoY); adjusted EBITDA of $1.31B (+32% YoY); adjusted EPS of $1.77 (+53% YoY). Company raised full-year 2026 revenue and adjusted EBITDA guidance. Board authorized $50M share repurchase program. BHC excluding Bausch+Lomb segment posted 14 consecutive quarters of YoY revenue and EBITDA growth, with adjusted EBITDA exceeding $1B for the first time.
Why this rating
Strong organic growth, margin expansion, and guidance raise are material; $50M buyback offsets dilution. Relative to $2B market cap, ~$300M EBITDA beat is ~15% favorable swing—real but not transformational. Tariff headwinds noted but not yet material.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.